Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06319950 | High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases | not yet recruiting | Phase 2 | 255 | Taizhou HospitalOTHER | 0 | Mar 20, 2024 | clinicaltrials |
| NCT06317896 | Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS | not yet recruiting | — | 82 | Zhujiang HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06314698 | Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease | not yet recruiting | Phase 3 | 478 | RenJi HospitalOTHER | 0 | Mar 18, 2024 | clinicaltrials |
| NCT06314828 | A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL | not yet recruiting | Phase 1 | 30 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 18, 2024 | clinicaltrials |
| NCT05425576 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | not yet recruiting | Phase 2 | 63 | Oncotelic Inc.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06259058 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06304818 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours. | not yet recruiting | Phase 1 / Phase 2 | 515 | Sinocelltech Ltd.INDUSTRY | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06310473 | Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | not yet recruiting | Phase 2 | 30 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06311916 | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. | not yet recruiting | Phase 4 | 312 | Chen XiaopingOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06313554 | Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | N/A | 63 | Fudan UniversityOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06304545 | Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab | not yet recruiting | Phase 2 | 48 | Harbin Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT06306560 | A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. | not yet recruiting | Phase 2 | 40 | Harbin Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT03763396 | Azoles Targeting Recurrent High Grade Gliomas | not yet recruiting | Early Phase 1 | 30 | University Health Network, TorontoOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06300216 | A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors | not yet recruiting | — | 500 | Qilu Hospital of Shandong UniversityOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06301386 | Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients | not yet recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06253598 | Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06298266 | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 15 | Guangdong Second Provincial General HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06298773 | Spatial Profile of Tumors(PROST) | not yet recruiting | — | 1,000 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06299371 | Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | not yet recruiting | Phase 2 | 36 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT05370300 | SNAPS Breast Cancer Patient Study Breast Cancer Patients | not yet recruiting | — | 500 | Immunis.AIINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06295029 | Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics | not yet recruiting | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Mar 6, 2024 | clinicaltrials |
| NCT06295094 | The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.(EPICURE) | not yet recruiting | Phase 2 | 264 | Odense University HospitalOTHER | 5 | Mar 6, 2024 | clinicaltrials |
| NCT06050941 | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | not yet recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Mar 5, 2024 | clinicaltrials |
| NCT06289959 | Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL | not yet recruiting | N/A | 30 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06286228 | Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease(Haplo) | not yet recruiting | — | 43 | Siriraj HospitalOTHER | 0 | Mar 1, 2024 | clinicaltrials |
| NCT06283121 | A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer | not yet recruiting | Phase 2 | 30 | China Medical University, ChinaOTHER | 0 | Feb 29, 2024 | clinicaltrials |
| NCT06116929 | Hodgkin's Disease and Chemotherapy Before 40 Years(FunC-AHOD) | not yet recruiting | N/A | 63 | Lille Catholic UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06195371 | Impact of CASP3 Gene in Chemoresistance | not yet recruiting | — | 60 | Gehad Salah El-Din shakerOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06233877 | Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer(GFLIPM) | not yet recruiting | Phase 2 | 60 | Hirschfeld OncologyOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06264505 | Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06270355 | Stockholm Mammography Risk Stratified Trial(SMART) | not yet recruiting | Phase 3 | 70,000 | Karolinska InstitutetOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06276153 | Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer(CRGGCext) | not yet recruiting | — | 5,000 | RenJi HospitalOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06282536 | Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial | not yet recruiting | Phase 2 | 20 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06276933 | A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 4 | 104 | Tongji UniversityOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT06277804 | A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor | not yet recruiting | Phase 1 | 48 | LetolabINDUSTRY | 0 | Feb 26, 2024 | clinicaltrials |
| NCT06278896 | Early Neutropenic Fever De-escalation of Antibiotics Study(END) | not yet recruiting | Phase 3 | 260 | Brigham and Women's HospitalOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT06255912 | Clinical Trial for Advanced or Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 26 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 23, 2024 | clinicaltrials |
| NCT06272162 | Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy(LAPSTAR) | not yet recruiting | N/A | 150 | UMC UtrechtOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06273553 | A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 | not yet recruiting | Phase 1 / Phase 2 | 39 | RinuaGene Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 22, 2024 | clinicaltrials |
| NCT06271551 | Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy(ESTRACISE) | not yet recruiting | Phase 2 | 310 | Central Finland Hospital DistrictOTHER | 0 | Feb 21, 2024 | clinicaltrials |
| NCT05707468 | Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer | not yet recruiting | N/A | 200 | Changhai HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06234150 | Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment(ADANC) | not yet recruiting | N/A | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06266975 | Chronic Kidney Disease Patient in Chronic Myloied Leukemia | not yet recruiting | — | 40 | Sahar Mohammed GadOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06268327 | Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 30 | Assiut UniversityOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT05807646 | Reduced Dissemination of Tumor Cells With Primary Ligation of the Inferior Mesenteric Vein in Rectal Cancer Patients. | not yet recruiting | N/A | 268 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | Feb 15, 2024 | clinicaltrials |
| NCT06180499 | Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion(ILDTreg2) | not yet recruiting | Phase 1 / Phase 2 | 27 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Feb 14, 2024 | clinicaltrials |
| NCT06255704 | A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients(Z+RCHOP/RDHAP) | not yet recruiting | Phase 2 | 23 | Shanxi Province Cancer HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255964 | A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 236 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Feb 13, 2024 | clinicaltrials |
| NCT06254599 | A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | not yet recruiting | Phase 3 | 255 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2024source: clinicaltrials